research project


CANDY is short for Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy. Many developmental brain conditions co-occur, meaning that if a person has one of those disorders they are quite likely to also have another one. For instance, in autism spectrum disorder, the combination of intellectual disability and epilepsy is associated with a reduction in lifespan of about 20 years; and an economic cost that is greater than cancer, stroke, or dementia. Yet, the research spend on neurodevelopmental diseases is less than 1% of the spending on cancer, stroke and dementia.

CANDY’s innovation is to test, for the first time, if those disorders and their common mental and bodily co-symptoms, are caused by combinations of common and rare genetic variants and immune activation acting at different ‘sensitive periods’. 

CANDY project

The role of Noldus

Noldus will further develop its innovative tools for neuroscience research using animal models to support the research in this project. Specifically it will both develop better tracking in its EthoVision XT software as well as improve the integration of physiology and behavioral measurements in EthoVision.

More information

To find out more, you can contact us directly or visit the project website. If you think Noldus might be a good partner for your consortium, please see here.


  • Radboud University Medical Centre, Nijmegen (Project Coordinator)
  • King's College London
  • Birkbeck, University of London
  • Institut Pasteur
  • University of Basel
  • University of Groningen
  • University of Ghent
  • Karolinska Institute
  • Assistance Publique des Hôpitaux de Paris
  • University of Ulm
  • CEA
  • Autism Europe
  • Noldus Information Technology


This project is funded by the Horizon 2020 research program of the European Union under grant number 847818.

Horizon 2020

CANDY project